Related Experiment Video
Updated: Aug 26, 2025

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
Published on: April 19, 2024
Tixagevimab/cilgavimab for prevention and treatment of COVID-19: a review
1Regional Infectious Diseases Unit, North Manchester General Hospital and Faculty of Biology, Medicine & Health, University of Manchester, Manchester, UK.
Introduction:
There is a need to protect vulnerable individuals who do not respond to vaccination against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), particularly following the emergence of new variants. Tixagevimab/cilgavimab, the only monoclonal antibody combination authorized for pre-exposure prophylaxis of coronavirus disease 2019 (COVID-19), demonstrated efficacy in unvaccinated individuals in the PROVENT study.
Areas Covered:
This review focuses predominantly on real-world evidence examining the effectiveness and safety of tixagevimab/cilgavimab in populations who are immunocompromised and otherwise vulnerable. The ability of tixagevimab/cilgavimab to neutralize Omicron subvariants, the appropriate dosage in vulnerable populations, and the impact of prior vaccination on tixagevimab/cilgavimab effectiveness are also discussed.
Expert Opinion:
The tixagevimab/cilgavimab combination is important in providing protection in people who either cannot have a full vaccination or respond poorly to COVID-19 vaccines. Abundant clinical data have emerged to inform clinical use in adults in need, although some additional data-formal pediatric and adolescent studies, plus information on optimal doses required to protect against emerging variants, and the ideal interval between tixagevimab/cilgavimab dosing and vaccination-would be welcomed. Importantly, despite the current effectiveness of tixagevimab/cilgavimab, we must recognize the possibility that resistant SARS-CoV-2 variants could emerge in the future.
Insights
Tixagevimab/cilgavimab offers crucial protection against COVID-19 for unvaccinated or poorly responding individuals. This review examines its real-world effectiveness and safety, especially for vulnerable populations facing new SARS-CoV-2 variants.
Area of Science:
- Immunology
- Virology
- Pharmacology
Background:
- Vulnerable populations, including the immunocompromised, require protection against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) due to inadequate vaccine response.
- The emergence of new SARS-CoV-2 variants necessitates ongoing strategies for prophylaxis.
- Tixagevimab/cilgavimab is the sole monoclonal antibody combination authorized for pre-exposure prophylaxis of coronavirus disease 2019 (COVID-19).
Conclusions:
- Tixagevimab/cilgavimab is vital for protecting individuals with poor vaccine response or contraindications to vaccination.
- Further research is needed on pediatric use, optimal dosing against variants, and vaccination intervals.
- Anticipation of potential resistant SARS-CoV-2 variants is crucial for future strategies.
More Related Videos
Related Concept Videos
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Immune Response Against Viral Pathogens
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
Subviral Agents
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:

